IgA-nefropátia: vizsgálatok itt: Dél-afrikai Köztársaság
1 trial · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisFut, nem toborozA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Where
- Bloemfontein
- Életkor
- 18 év to 100 év
- People
- 540 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00